NYSE: ABBVAbbVie Inc Stock Forecast, Predictions & Price Target
Analyst price target for ABBV
Based on 13 analysts offering 12 month price targets for AbbVie Inc.
Min Forecast
$96.00+13.95%
Avg Forecast
$108.54+28.83%
Max Forecast
$127.00+50.74%
Should I buy or sell ABBV stock?
Strong Buy
Strong Buy
9 analysts 60.00%
Buy
1 analysts 6.67%
Hold
5 analysts 33.33%
Sell
0 analysts 0.00%
Strong Sell
0 analysts 0.00%
Forecast return on equity
Is ABBV forecast to generate an efficient return?
Company
139.16%
Industry
55.96%
Market
-1.56%
ABBV's Return on Equity is forecast to be high in 4 years (139.16%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast
Forecast return on assets
Is ABBV forecast to generate an efficient return on assets?
Company
13.69%
Industry
15.11%
Market
11.47%
ABBV is forecast to generate lower Return on Assets (13.69%) than the US Drug Manufacturers - General industry average (15.11%)
Forecast
ABBV earnings per share forecast
What is ABBV's earnings per share in the next 3 years based on estimates from 7 analysts?
Avg 1 year Forecast
$10.45+121.37%
Avg 2 year Forecast
$12.17+157.87%
Avg 3 year Forecast
$13.53+186.55%
ABBV's earnings are forecast to grow at an exceptional rate of 42.37% per year
Forecast
ABBV revenue forecast
What is ABBV's revenue in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
$45.4B+25.36%
Avg 2 year Forecast
$53.5B+47.75%
Avg 3 year Forecast
$57.2B+57.77%
ABBV's revenue is forecast to grow at a rate of 16.92% per year, which is not exceptional
Forecast
ABBV earnings growth forecast
How is ABBV forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
42.37%
Industry
20.03%
Market
14.71%
ABBV's earnings are forecast to grow faster (42.37% per year) than the US Drug Manufacturers - General industry average (20.03%)
Forecast
ABBV's earnings are forecast to grow faster (42.37% per year) than the US market average (14.71%)
Forecast
ABBV revenue growth forecast
How is ABBV forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
16.92%
Industry
6.43%
Market
5.62%
ABBV's revenues are forecast to grow faster (16.92% per year) than the US Drug Manufacturers - General industry average (6.43%)
Forecast
ABBV's revenues are forecast to grow faster (16.92% per year) than the US market average (5.62%)
Forecast
AbbVie Stock Forecast FAQ
Is AbbVie Stock a good buy in 2020, according to Wall Street analysts?
The consensus among 15 Wall Street analysts covering (NYSE: ABBV) stock is to Strong Buy ABBV stock.
Out of 15 analysts, 9 (60.00%) are recommending ABBV as a Strong Buy, 1 (6.67%) are recommending ABBV as a Buy, 5 (33.33%) are recommending ABBV as a Hold, 0 (0.00%) are recommending ABBV as a Sell, and 0 (0.00%) are recommending ABBV as a Strong Sell.
What is ABBV's Price Target?
According to 13 Wall Street analysts that have issued a 1 year ABBV price target, the average ABBV price target is $108.54, with the highest ABBV stock price forecast at $127.00 and the lowest ABBV stock price forecast at $96.00.
On average, Wall Street analysts predict that AbbVie's share price could reach $108.54 by Oct 16, 2021. The average AbbVie stock price prediction forecasts a potential upside of 28.83% from the current ABBV share price of $84.25.
What is ABBV's earnings growth forecast for 2020-2022?
(NYSE: ABBV) AbbVie's forecast annual earnings growth rate of 42.37% is forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 20.03%, and and it is also forecast to beat the US market's average forecast earnings growth rate of 14.71%.
AbbVie's earnings in 2020 is $6,957,000,000.On average, 7 Wall Street analysts forecast ABBV's earnings for 2020 to be $15,429,888,708, with the lowest ABBV earnings forecast at $15,284,281,925, and the highest ABBV earnings forecast at $15,771,606,856. On average, 7 Wall Street analysts forecast ABBV's earnings for 2021 to be $17,974,020,196, with the lowest ABBV earnings forecast at $17,720,906,580, and the highest ABBV earnings forecast at $18,341,138,310.
In 2022, ABBV is forecast to generate $19,972,938,458 in earnings, with the lowest earnings forecast at $19,684,973,726 and the highest earnings forecast at $20,600,553,899.
What is ABBV's revenue growth forecast for 2020-2022?
(NYSE: ABBV) AbbVie's forecast annual revenue growth rate of 16.92% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.43%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 5.62%.
AbbVie's revenue in 2020 is $36,227,000,000.On average, 4 Wall Street analysts forecast ABBV's revenue for 2020 to be $67,065,730,834,450, with the lowest ABBV revenue forecast at $66,956,894,933,204, and the highest ABBV revenue forecast at $67,154,852,227,125. On average, 4 Wall Street analysts forecast ABBV's revenue for 2021 to be $79,041,977,291,300, with the lowest ABBV revenue forecast at $77,930,640,169,980, and the highest ABBV revenue forecast at $79,627,697,556,036.
In 2022, ABBV is forecast to generate $84,404,057,808,810 in revenue, with the lowest revenue forecast at $82,061,088,145,335 and the highest revenue forecast at $85,407,386,004,525.
What is ABBV's Earnings Per Share (EPS) forecast for 2020-2022?
(NYSE: ABBV) AbbVie's current Earnings Per Share (EPS) is $4.72. On average, analysts forecast that ABBV's EPS will be $10.45 for 2020, with the lowest EPS forecast at $10.35, and the highest EPS forecast at $10.68. On average, analysts forecast that ABBV's EPS will be $12.17 for 2021, with the lowest EPS forecast at $12.00, and the highest EPS forecast at $12.42. In 2022, ABBV's EPS is forecast to hit $13.53 (min: $13.33, max: $13.95).
What is ABBV's forecast return on equity (ROE) for 2020-2023?
(NYSE: ABBV) forecast ROE is 139.16%, which is considered strong.
What is ABBV's forecast return on assets (ROA) for 2020-2023?
(NYSE: ABBV) forecast ROA is 13.69%, which is lower than the forecast US Drug Manufacturers - General industry average of 15.11%.
©2020 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
